| Oct 7 |
Nuvation Bio names Philippe Sauvage CFO
|
| Oct 7 |
Nuvation Bio Appoints Industry Veteran Philippe Sauvage as Chief Financial Officer
|
| Oct 2 |
Navigating Legal Uncertainty: Nuvation Bio Inc.’s Chinese Operations and the Shifting Landscape of China’s Civil Law System
|
| Sep 14 |
Positive Pooled Data from Nuvation Bio’s TRUST-I and TRUST-II Studies Highlight Taletrectinib’s Best-in-Class Potential for Patients with Advanced ROS1-positive NSCLC, Supporting Planned New Drug Application Submission in the Fourth Quarter of 2024
|
| Sep 9 |
Nuvation Bio to Present at the Cantor Global Healthcare Conference
|
| Aug 22 |
With 47% stake, Nuvation Bio Inc. (NYSE:NUVB) seems to have captured institutional investors' interest
|
| Aug 8 |
Nuvation Bio: Continuing To Justify A Buy Thesis With Catalysts In 2024
|
| Aug 6 |
Nuvation Bio pauses oncology drug after Phase I efficacy and safety analysis
|
| Aug 5 |
Nuvation Bio GAAP EPS of -$1.89 misses by $1.73, revenue of $1.44M
|
| Aug 5 |
Small-Cap Cancer-Focused Nuvation Bio Pulls Plug On Early-Stage Program After Considering Phase 1 Solid Tumor Data
|
